The glycemic index: where are we now and where are we going?

被引:0
|
作者
Brand-Miller, J [1 ]
机构
[1] Univ Sydney, Sydney, NSW 2006, Australia
来源
FOOD AUSTRALIA | 2005年 / 57卷 / 05期
关键词
D O I
暂无
中图分类号
TS2 [食品工业];
学科分类号
0832 ;
摘要
From controversial beginnings in the 1980s, the glycemic index (GI) has stood the test of time and scientific scrutiny. It is now considered a fundamental concept in nutrition science and is the subject of hundreds of scientific papers each year, some of them in the highest impact medical journals (Pawlak & others 2004). Officially, the GI is recommended by major diabetes associations, including Diabetes UK (2003), Canadian Diabetes Association (2000) and Diabetes Australia (Barclay 1998). Most recently, the American Diabetes Association officially recognised that the GI 'can provide an additional benefit over that observed when total carbohydrate is considered alone' (Sheard & others 2004). The application of the GI in other areas, eg weight control (Ebbeling & others 2003), sports performance (Burke & others 1993), cardiovascular disease (Brynes & others 2003), cancer prevention (Francheschi 1996, Francheschi & others 1997), is the subject of ongoing research. While the evidence base is still limited, the GI is being applied to the management of all the diseases linked to insulin resistance, including the metabolic syndrome, polycystic ovary syndrome (PCOS) (Marsh & Brand-Miller 2005), non-alcoholic fatty liver disease (NAFLD), and in novel areas such as cognitive performance, memory and learning (Benton & others 2003).
引用
收藏
页码:200 / 204
页数:5
相关论文
共 50 条
  • [41] Retirement income in America: Where are we now and where are we going?
    Salisbury, DL
    RETIREMENT PROSPECTS IN A DEFINED CONTRIBUTION WORLD, 1997, : 11 - 20
  • [42] The Society for Nautical Research: Where are we now and where are we going?
    Harding, Richard
    MARINERS MIRROR, 2011, 97 (01): : 10 - 21
  • [43] Where are we now, and where are we going? Perspectives on cosmic abundances
    Beers, TC
    COSMIC ABUNDANCES AS RECORDS OF STELLAR EVOLUTION AND NUCLEOSYNTHESIS IN HONOR OF DAVID L. LAMBERT, 2005, 336 : 283 - 288
  • [44] Information technology and productivity: Where are we now and where are we going?
    Oliner, SD
    Sichel, DE
    TECHNOLOGY, GROWTH, AND THE LABOR MARKET, 2003, : 41 - 94
  • [45] Immunotherapies in Genitourinary Oncology: Where Are We Now? Where Are We Going?
    Jang, Albert
    Adler, David M.
    Rauterkus, Grant P.
    Bilen, Mehmet A.
    Barata, Pedro C.
    CANCERS, 2021, 13 (20)
  • [46] Immunosuppression for kidney transplantation: Where are we now and where are we going?
    Lim, Mary Ann
    Kohli, Jatinder
    Bloom, Roy D.
    TRANSPLANTATION REVIEWS, 2017, 31 (01) : 10 - 17
  • [47] HIV prevention 2010: where are we now and where are we going?
    Cohen, Myron S.
    Fidler, Sarah
    CURRENT OPINION IN HIV AND AIDS, 2010, 5 (04) : 265 - 268
  • [48] Management of indolent lymphoma: Where are we now and where are we going
    Lunning, Matthew A.
    Vose, Julie M.
    BLOOD REVIEWS, 2012, 26 (06) : 279 - 288
  • [49] Alzheimer's genetics: Where are we now, and where are we going?
    Blacker, D
    NEUROBIOLOGY OF AGING, 2004, 25 : S26 - S26
  • [50] Prevention of Ovarian Cancer: Where are We Now and Where are We Going?
    Rodriguez, Isabel V.
    Ghezelayagh, Talayeh
    Pennington, Kathryn P.
    Norquist, Barbara M.
    CURRENT ONCOLOGY REPORTS, 2024, : 1355 - 1366